- Home
- DQ vs PHAT Comparison
DQ vs PHAT Comparison
Compare DQ & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DQ | PHAT |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 877.0M | 969.8M |
| IPO Year | 2010 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DQ | PHAT |
|---|---|---|
| Price | $12.63 | $9.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $28.91 | $19.83 |
| AVG Volume (30 Days) | 1.0M | ★ 1.3M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | $69.82 | $93.04 |
| Revenue Next Year | $34.34 | $58.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $11.38 | $8.21 |
| 52 Week High | $36.59 | $18.31 |
Technical Indicators
Market Signals| Indicator | DQ | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 43.81 | 52.01 |
| Support Level | $11.47 | $8.31 |
| Resistance Level | $15.22 | $9.75 |
| Average True Range (ATR) | 0.76 | 0.45 |
| MACD | -0.18 | 0.15 |
| Stochastic Oscillator | 11.90 | 84.76 |
Price Performance
Historical ComparisonAbout DQ DAQO New Energy Corp.
Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.